Filtered By:
Condition: Heart Failure
Drug: Pradaxa

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 109 results found since Jan 2013.

Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real ‐world analysis
ConclusionIn obese patients with congestive heart failure and atrial fibrillation or atrial flutter on DOACs, apixaban has the most favorable safety profile compared to rivaroxaban and dabigatran.
Source: Pacing and Clinical Electrophysiology : PACE - December 2, 2022 Category: Cardiology Authors: Yashasvi Chugh, Kashvi Gupta, Hanumanthu Balram Krishna, Renato Quispe Ayala, Ignacio Zepeda, Michael Grushko, Robert T Faillace Tags: ORIGINAL ARTICLE Source Type: research

Anticoagulation in Patients with Dilated Cardiomyopathy, Low Ejection Fraction, and Sinus Rhythm: Back to the Drawing Board
Summary Heart failure patients present an important thrombo‐embolic risk, including symptomatic or silent peripheral arterial embolism, pulmonary embolism, and stroke. Patients in sinus rhythm who have concomitant depressed (<35%) left ventricular ejection fraction have a 4% rate of embolic events. Several prospective randomized trials of anticoagulation in this group of patients were either underpowered or had a short period of follow‐up. Even though in two studies warfarin had a slight advantage over aspirin (in the WATCH and WARCEF trials), it was at the cost of an increased risk in major hemorrhage. To decrease ...
Source: Cardiovascular Therapeutics - September 12, 2013 Category: Cardiology Authors: Alexandru Nicolae Mischie, Valentin Chioncel, Ionel Droc, Crina Sinescu Tags: Short communication Source Type: research

Direct Oral Anticoagulants in Atrial Fibrillation
Atrial fibrillation (AF), the most frequent sustained arrhythmia, is associated with an increased risk of thromboembolic events. The risk of stroke depends on risk factors such as age, hypertension, heart failure, and vascular disease. Thus, antithrombotic therapy is a cornerstone in the management of AF. Warfarin is successfully used to reduce thromboembolic events. More recently, direct thrombin (dabigatran) and factor Xa (apixaban, edoxaban, rivaroxaban) inhibitors have been compared to warfarin in large randomized trials. All new substances have been shown to be non-inferior to warfarin concerning thromboembolic events...
Source: Seminars in Hematology - April 9, 2014 Category: Hematology Authors: Georg Noll, Sarah Noll, David Hürlimann Source Type: research

Abstract 161: Atrial Fibrillation in India: Insights from the PINNACLE India Outpatient Registry Session Title: Poster Session I
Conclusion: AF is tough to diagnose since it is often asymptomatic and clinicians need many tests to confirm diagnosis. Lack of documentation or detection of AF and its associated conditions is a concern. AF can lead to life threatening problems such as stroke and heart failure. The surveillance of AF in India is important in order to identify opportunities for intervention. Continued data collection through the use of a cardiovascular registry can improve the understanding of AF in India.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Glusenkamp, N. T., Risch, S. A., Kerkar, P., Kumar, G., Oetgen, W. J. Tags: Session Title: Poster Session I Source Type: research

Comparison of warfarin time in the therapeutic range at a pharmacist-run anticoagulation clinic and the RE-LY trial.
CONCLUSION: TTR values among PAC-managed patients with nonvalvular atrial fibrillation were comparable to those reported in the RE-LY trial. PMID: 25788509 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - March 20, 2015 Category: Drugs & Pharmacology Authors: Biszewski M, Nitzki-George D, Zhou Y Tags: Am J Health Syst Pharm Source Type: research

Abstract 152: Persistence of Warfarin versus Dabigatran Therapy in Patients with Atrial Fibrillation: Results from the ORBIT AF Registry Session Title: Poster Session I
Conclusion: Persistence rates for warfarin were higher at one year than those on dabigatran. In addition, factors associated with persistence of warfarin include: African American and Hispanic race, type of AF including permanent and persistent, LVH, and CHA2DS2-VASc risk scores ≥ 2.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Jackson, L. R., Kim, S., Shrader, P., Blanco, R., Thomas, L., Ansell, J., Fonarow, G. C., Gersh, B. J., Go, A. S., Kowey, P., Mahaffey, K. W., Hylek, E. M., Burton, P., Peterson, E. D., Piccini, J. P. Tags: Session Title: Poster Session I Source Type: research

Predictors of Gastrointestinal Bleeding Among Patients with Atrial Fibrillation After Initiating Dabigatran Therapy
ConclusionThe risk of GI bleeding in patients receiving dabigatran is highly associated with increased age and cardiovascular, renal, and other comorbidities, even after adjusting for other factors. Fewer than 50% of patients restarted an anticoagulant after experiencing a GI bleed. Clinicians should continue to monitor for these risk factors or consider whether alternative therapies may be appropriate.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 1, 2015 Category: Drugs & Pharmacology Authors: Julie C. Lauffenburger, Denise H. Rhoney, Joel F. Farley, Anil K. Gehi, Gang Fang Tags: Original Research Article Source Type: research

Patient Characteristics and Risk of Bleeding With Dabigatran
To the Editor We appreciate the interesting study by Hernandez et al on the risk of bleeding with dabigatran in patients with atrial fibrillation. These are important data to an ongoing controversy. However, we would appreciate an author comment regarding the external validity of the study. To what extent is this sample of Medicare beneficiaries representative of the general population of patients with atrial fibrillation? Comparing the characteristics of patients in the RE-LY Study and the Danish population-based study, it seems that these are not effortlessly comparable. In the study by Hernandez et al, patients are cons...
Source: JAMA Internal Medicine - July 1, 2015 Category: Internal Medicine Source Type: research

Dabigatran for left ventricular thrombus
Publication date: Available online 8 August 2015 Source:Indian Heart Journal Author(s): Satishkumar Kolekar, Chandrashekhar Munjewar, Satyavan Sharma Male patient in dilated phase of hypertrophic cardiomyopathy had multiple hospitalizations during the past 2 years either due to congestive heart failure, stroke, scar epilepsy, or atrial fibrillation and ventricular tachycardia. Medication included evidence based therapy for heart failure, cordarone and warfarin. Anticoagulation had to be discontinued due to marked fluctuations in INR. Transthoracic Echocardiography (TTE) revealed a mobile mass in the left ventricle. He...
Source: Indian Heart Journal - August 8, 2015 Category: Cardiology Source Type: research

Dabigatran for left ventricular thrombus.
Abstract Male patient in dilated phase of hypertrophic cardiomyopathy had multiple hospitalizations during the past 2 years either due to congestive heart failure, stroke, scar epilepsy, or atrial fibrillation and ventricular tachycardia. Medication included evidence based therapy for heart failure, cordarone and warfarin. Anticoagulation had to be discontinued due to marked fluctuations in INR. Transthoracic Echocardiography (TTE) revealed a mobile mass in the left ventricle. He was treated with Dabigatran 110mg twice a day for 4 months without any bleeding or embolic episode and complete resolution of thrombus. ...
Source: Indian Heart J - September 1, 2015 Category: Cardiology Authors: Kolekar S, Munjewar C, Sharma S Tags: Indian Heart J Source Type: research

Dabigatran etexilate as second-line therapy in patients with a left ventricular assist device.
CONCLUSIONS: The safe and effective use of dabigatran as a second-line anticoagulation therapy in patients with HMII seems feasible. However, these data must be confirmed in a randomized study. PMID: 25701968 [PubMed - in process]
Source: Hellenic Journal of Cardiology - November 18, 2015 Category: Cardiology Tags: Hellenic J Cardiol Source Type: research

Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment.
We report a case of dabigatran intoxication in an elderly man affected by heart failure and worsening renal function, who developed acute hepatitis and coma, which was successfully treated with continuous veno-venous hemodiafiltration. Although extracorporeal therapy has been suggested as a strategy for clearing dabigatran during acute bleeding, this approach may be useful in other dabigatran-related, life-threatening conditions, such as that described in this report. PMID: 27910004 [PubMed - as supplied by publisher]
Source: International Journal of Hematology - November 30, 2016 Category: Hematology Authors: Porru M, Mameli A, Cianchetti ME, Musu M, Schirru P, Ruberto MF, Barcellona D, Marongiu F Tags: Int J Hematol Source Type: research

Trends in the prescription of novel oral anticoagulants in UK primary care
ConclusionsIn the UK, the initiation of NOAC has increased substantially since 2009, and NOAC have now surpassed VKA as the anticoagulant of choice. Moreover, the characteristics of patients initiated on NOAC have changed over time, and this should be accounted for in future studies comparing NOAC and VKA.
Source: British Journal of Clinical Pharmacology - April 1, 2017 Category: Drugs & Pharmacology Authors: S. Y. Loo, S. Dell'Aniello, L. Huiart, C. Renoux Tags: PHARMACOEPIDEMIOLOGY Source Type: research

Anticoagulation in atrial fibrillation with heart failure
AbstractHeart failure (HF) and atrial fibrillation (AF) frequently coexist, and they can beget one another due to similar factors and shared pathophysiology. These pathophysiologic changes promote the episodes of AF, while they in turn predispose to the exacerbation of HF. In this review, we will discuss pathophysiological mechanisms shared by AF and HF. Patients with concomitant HF and AF are at a particularly high risk of thromboembolism, which contribute to even worse symptoms and poorer prognosis. Vitamin K antagonists (VKA) (warfarin) were the traditional medication in AF patients for the prevention of stroke, whereas...
Source: Heart Failure Reviews - March 22, 2018 Category: Cardiology Source Type: research

Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation
ConclusionIn a contemporary setting among VKA-experienced NVAF patients; VKA is still prevalent although about 30% by December 2015 had shifted to a NOAC.
Source: Europace - June 28, 2017 Category: Cardiology Source Type: research